Sézary syndrome without erythroderma.

[1]  M. Goswami,et al.  A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone , 2013, International journal of dermatology.

[2]  M. Jonkman,et al.  Bullous pemphigoid as pruritus in the elderly: a common presentation. , 2013, JAMA dermatology.

[3]  L. Michel,et al.  Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis. , 2013, Blood.

[4]  A. Weaver,et al.  Sézary syndrome: a study of 176 patients at Mayo Clinic. , 2012, Journal of the American Academy of Dermatology.

[5]  Wei Wei,et al.  Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.

[6]  G. Courtois,et al.  Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. , 2012, Blood.

[7]  M. Martinka,et al.  Molecular markers of early-stage mycosis fungoides. , 2012, The Journal of investigative dermatology.

[8]  M. Goswami,et al.  Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome , 2012, Journal of cutaneous pathology.

[9]  Wei Wei,et al.  Cancer Therapy : Clinical Long-term Outcomes of 1 , 263 Patients with Mycosis Fungoides and S ezary Syndrome from 1982 to 2009 , 2012 .

[10]  P. Porcu,et al.  Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome) , 2011, British journal of haematology.

[11]  S. Swerdlow,et al.  Primary cutaneous marginal zone lymphoma with subclinical cutaneous involvement and biclonality , 2011, Journal of cutaneous pathology.

[12]  J. Scarisbrick,et al.  Nonerythrodermic Sézary syndrome , 2011, Clinical and experimental dermatology.

[13]  S. Ansell,et al.  Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome , 2011, American journal of hematology.

[14]  R. Advani,et al.  Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). , 2011, Journal of the American Academy of Dermatology.

[15]  P. Porcu,et al.  T‐plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression , 2010, The British journal of dermatology.

[16]  M. Bagot,et al.  Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome , 2010, The British journal of dermatology.

[17]  O. Sanmartı́n,et al.  Images in clinical medicine. Fluorescence diagnosis of subclinical actinic keratoses. , 2008, The New England journal of medicine.

[18]  G. Bowen,et al.  CD158k/KIR3DL2 is a useful marker for identifying neoplastic T‐cells in Sézary syndrome by flow cytometry , 2008, Cytometry. Part B, Clinical cytometry.

[19]  K. Leroy,et al.  CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome. , 2008, The Journal of investigative dermatology.

[20]  C. Thoburn,et al.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma , 2008, Leukemia & lymphoma.

[21]  B. Thiers.  Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) , 2008 .

[22]  K. Rossen,et al.  FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival , 2007, Leukemia.

[23]  R. Willemze,et al.  Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.

[24]  J. Muche,et al.  Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. , 2003, The Journal of investigative dermatology.

[25]  J. Nicolas,et al.  Innate CD4+CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation. , 2003, Blood.

[26]  Louise C. Showe,et al.  Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma , 2003, The Journal of experimental medicine.

[27]  P. Ali,et al.  Sezary syndrome--without erythroderma. , 2002 .

[28]  E. Llistosella,et al.  Invisible mycosis fungoides: a diagnostic challenge. , 2002, Journal of the American Academy of Dermatology.

[29]  G. Burg,et al.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. , 2002, Journal of the American Academy of Dermatology.

[30]  M. Duvic,et al.  "Invisible" mycosis fungoides? , 2001, Journal of the American Academy of Dermatology.

[31]  J. Guilhou,et al.  Invisible mycosis fungoides: a new case. , 2001, Journal of the American Academy of Dermatology.

[32]  R. Bergman,et al.  Histopathologic Findings in the Clinically Uninvolved Skin of Patients with Mycosis Fungoides , 1995, The American Journal of dermatopathology.

[33]  A. Kligman,et al.  The invisible dermatoses. , 1991, Archives of dermatology.

[34]  S. Haldar,et al.  Tuberculoid granuloma in a clinically normal looking skin. , 1988, Indian journal of leprosy.

[35]  I. Braverman,et al.  Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation. , 1987, Journal of the American Academy of Dermatology.

[36]  C. Lewis,et al.  Invisible dermatoses. , 1978, Cutis.

[37]  T. Rea,et al.  Apparently normal skin in lepromatous leprosy: histopathological findings. , 1975, Archives of dermatology.

[38]  Muller Sa,et al.  Unusual variations of lichen planus. , 1966 .